MATTHEW SARCONA: Open Payments
NPI 1427603604 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$333 in 14 payments from 8 companies in 2025. Trend: 2023 $177 · 2024 $241 · 2025 $333
Food & beverage: $333
| Company | Payments | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 3 | $77 |
| BridgeBio Pharma, Inc. | 4 | $77 |
| Kestra Medical Technology Services, Inc. | 1 | $46 |
| Novo Nordisk Inc | 2 | $40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $26 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
Products named: AMVUTTRA, Attruby, Assure WCD, Wegovy, JARDIANCE, CAMZYOS, WAINUA, UPTRAVI.
Industry payments across NY — which companies pay providers there.
